论文部分内容阅读
目的对前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的疗效进行讨论分析。方法选取66例糖尿病患者,将其随机平均分为两组,对照组患者33例,观察组患者33例。对照组患者采用贝那普利治疗法,观察组患者采用贝那普利联合前列地尔治疗法。观察并记录两组患者不良反应、尿微蛋白排泄率、尿蛋白含量等方面的情况。结果对照组与观察组患者治疗有效率分别为78.79%与93.94%,P<0.05差异有统计学意义,两组患者经治疗后尿蛋白含量、尿微蛋白排泄率两方面的指标均有所降低,观察组患者在这两方面的情况均优于对照组,P<0.05差异有统计学意义。对照组与观察组两组患者的不良反应发生率分别为9.09%和6.06%,P>0.05差异无统计学意义。结论前列地尔联合贝那普利治疗糖尿病肾病蛋白尿临床效果明显,不良反应率显著降低,值得推广。
Objective To investigate the effects of alprostadil combined with benazepril in the treatment of diabetic nephropathy proteinuria. Methods Sixty-six patients with diabetes mellitus were selected and randomly divided into two groups: 33 patients in the control group and 33 patients in the observation group. Patients in the control group were treated with benazepril, and patients in the observation group were treated with benazepril and alprostadil. Observe and record two groups of patients with adverse reactions, urinary microalbuminuria, urinary protein content and so on. Results The effective rates of the control group and the observation group were 78.79% and 93.94%, respectively, with significant difference at P <0.05. Both the urinary protein and urinary microalbumin excretion rate decreased after treatment , The observation group patients in these two aspects are better than the control group, P <0.05 the difference was statistically significant. Adverse reactions in the control group and observation group were 9.09% and 6.06%, respectively, with no significant difference in P> 0.05. Conclusion Alprostadil combined with benazepril treatment of diabetic nephropathy proteinuria clinical effect, adverse reaction rate was significantly reduced, it is worth promoting.